|

Liver Disease Clinical Trials in Alabama

27 recruiting studies across 5 cities

All Trials in Alabama

Phase
Trial Phase Location
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)Phase 3Birmingham
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsPhase 1/2Birmingham
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPhase 3Birmingham
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Phase 3Birmingham
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1Birmingham
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaPhase 1/2Birmingham
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCPhase 1/2Birmingham
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPhase 3Birmingham
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)Phase 1/2Birmingham
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIVPhase 2Birmingham
DESTINY-PANTUMOUR04—Birmingham
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)—Birmingham
Genetic Variation in IgG in Alpha 1 Antitrypsin DeficiencyPhase 4Birmingham
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisPhase 3Birmingham
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)—Birmingham
Longitudinal Study of the Porphyrias—Birmingham
PiMZ Longitudinal Cohort (PiMZ Logic)—Birmingham
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRIN/ABirmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Birmingham
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPhase 3Birmingham
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCCPhase 1/2Birmingham
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin ProteinPhase 3Birmingham
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)Phase 3Birmingham
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPhase 1/2Birmingham
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialPhase 3Birmingham
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver CancerPhase 1Dothan
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Phase 3Tuscaloosa

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.